Exploring the Advantages of Quantum Generative Adversarial Networks in Generative Chemistry.


Journal

Journal of chemical information and modeling
ISSN: 1549-960X
Titre abrégé: J Chem Inf Model
Pays: United States
ID NLM: 101230060

Informations de publication

Date de publication:
12 06 2023
Historique:
medline: 13 6 2023
pubmed: 12 5 2023
entrez: 12 5 2023
Statut: ppublish

Résumé

De novo drug design with desired biological activities is crucial for developing novel therapeutics for patients. The drug development process is time- and resource-consuming, and it has a low probability of success. Recent advances in machine learning and deep learning technology have reduced the time and cost of the discovery process and therefore, improved pharmaceutical research and development. In this paper, we explore the combination of two rapidly developing fields with lead candidate discovery in the drug development process. First, artificial intelligence has already been demonstrated to successfully accelerate conventional drug design approaches. Second, quantum computing has demonstrated promising potential in different applications, such as quantum chemistry, combinatorial optimizations, and machine learning. This article explores hybrid quantum-classical generative adversarial networks (GAN) for small molecule discovery. We substituted each element of GAN with a variational quantum circuit (VQC) and demonstrated the quantum advantages in the small drug discovery. Utilizing a VQC in the noise generator of a GAN to generate small molecules achieves better physicochemical properties and performance in the goal-directed benchmark than the classical counterpart. Moreover, we demonstrate the potential of a VQC with only tens of learnable parameters in the generator of GAN to generate small molecules. We also demonstrate the quantum advantage of a VQC in the discriminator of GAN. In this hybrid model, the number of learnable parameters is significantly less than the classical ones, and it can still generate valid molecules. The hybrid model with only tens of training parameters in the quantum discriminator outperforms the MLP-based one in terms of both generated molecule properties and the achieved KL divergence. However, the hybrid quantum-classical GANs still face challenges in generating unique and valid molecules compared to their classical counterparts.

Identifiants

pubmed: 37171372
doi: 10.1021/acs.jcim.3c00562
pmc: PMC10268960
doi:

Substances chimiques

Pharmaceutical Preparations 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3307-3318

Références

IEEE Trans Pattern Anal Mach Intell. 2021 Dec;43(12):4217-4228
pubmed: 32012000
Science. 2020 Aug 28;369(6507):1084-1089
pubmed: 32855334
Science. 2005 Sep 9;309(5741):1704-7
pubmed: 16151006
Oncotarget. 2017 Nov 9;9(5):5665-5690
pubmed: 29464026
Expert Opin Drug Discov. 2019 Aug;14(8):791-803
pubmed: 31179763
J Phys Chem A. 2021 Mar 11;125(9):1827-1836
pubmed: 33635672
J Cheminform. 2009 Jun 10;1(1):8
pubmed: 20298526
Nat Chem. 2012 Jan 24;4(2):90-8
pubmed: 22270643
Sci Data. 2014 Aug 05;1:140022
pubmed: 25977779
Sci Rep. 2019 Dec 11;9(1):18911
pubmed: 31827124
Nat Biotechnol. 2019 Sep;37(9):1038-1040
pubmed: 31477924
J Chem Inf Model. 2012 Nov 26;52(11):2864-75
pubmed: 23088335
Trends Pharmacol Sci. 2019 Aug;40(8):592-604
pubmed: 31320117
J Chem Inf Model. 2023 Feb 13;63(3):695-701
pubmed: 36728505
J Chem Inf Model. 2019 Mar 25;59(3):1096-1108
pubmed: 30887799
Nat Chem. 2010 Feb;2(2):106-11
pubmed: 21124400
Nat Rev Drug Discov. 2005 Aug;4(8):649-63
pubmed: 16056391
Int J Mol Sci. 2021 Feb 07;22(4):
pubmed: 33562347
Drug Discov Today. 2021 Jan;26(1):80-93
pubmed: 33099022
J Cheminform. 2019 Dec 3;11(1):74
pubmed: 33430938
JAMA. 2020 Mar 03;323(9):844-853
pubmed: 32125404
ACS Med Chem Lett. 2020 Jul 14;11(8):1496-1505
pubmed: 32832015
AAPS J. 2022 Jan 4;24(1):19
pubmed: 34984579
Mol Pharm. 2018 Oct 1;15(10):4311-4313
pubmed: 30269508
Chem Rev. 2019 Oct 9;119(19):10856-10915
pubmed: 31469277
Future Med Chem. 2018 Sep 1;10(17):2021-2024
pubmed: 30058835
Nat Commun. 2014 Jul 23;5:4213
pubmed: 25055053
Phys Rev Lett. 2022 Mar 18;128(11):110501
pubmed: 35363009
Oncotarget. 2017 Feb 14;8(7):10883-10890
pubmed: 28029644
Comput Struct Biotechnol J. 2021 Aug 12;19:4538-4558
pubmed: 34471498
Comput Biol Med. 2022 Jun;145:105403
pubmed: 35339849
Mol Pharm. 2016 Jul 5;13(7):2524-30
pubmed: 27200455
Nature. 2017 Sep 13;549(7671):242-246
pubmed: 28905916
Phys Rev Lett. 2018 Jul 27;121(4):040502
pubmed: 30095952
Mol Pharm. 2017 Sep 5;14(9):3098-3104
pubmed: 28703000
J Chem Inf Model. 2020 Dec 28;60(12):5682-5698
pubmed: 32686938
Front Pharmacol. 2020 Dec 18;11:565644
pubmed: 33390943

Auteurs

Po-Yu Kao (PY)

Insilico Medicine Taiwan Ltd., Taipei 110208, Taiwan.

Ya-Chu Yang (YC)

Insilico Medicine Taiwan Ltd., Taipei 110208, Taiwan.

Wei-Yin Chiang (WY)

Hon Hai (Foxconn) Research Institute, Taipei 114699, Taiwan.

Jen-Yueh Hsiao (JY)

Hon Hai (Foxconn) Research Institute, Taipei 114699, Taiwan.

Yudong Cao (Y)

Zapata Computing, Inc., Boston, Massachusetts 02110, United States.

Alex Aliper (A)

Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE.

Feng Ren (F)

Insilico Medicine Shanghai Ltd., Shanghai 201203, China.

Alán Aspuru-Guzik (A)

Department of Chemistry, University of Toronto, Toronto, ON M5S 3H6, Canada.
Department of Computer Science, University of Toronto, Toronto, ON M5S 2E4, Canada.
Vector Institute for Artificial Intelligence, Toronto, ON M5S 1M1, Canada.
Lebovic Fellow, Canadian Institute for Advanced Research, Toronto, ON M5S 1M1, Canada.

Alex Zhavoronkov (A)

Insilico Medicine Hong Kong Ltd., Hong Kong SAR, 999077, China.

Min-Hsiu Hsieh (MH)

Hon Hai (Foxconn) Research Institute, Taipei 114699, Taiwan.

Yen-Chu Lin (YC)

Insilico Medicine Taiwan Ltd., Taipei 110208, Taiwan.
Department of Pharmacy, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH